CVS HEALTH Corp: Form 10-K for the period ended Dec 31, 2012
Filed with the SEC on Feb 15, 2013 and accepted by EDGAR at Feb 15, 2013, 17:28 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2012-10-01 to 2012-12-31 | $31.39bn | us-gaap:Revenues |
| Revenue | 12 months2012-01-01 to 2012-12-31 | $123.13bn | us-gaap:Revenues |
| Cost of revenue | 12 months2012-01-01 to 2012-12-31 | $100.63bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months2012-10-01 to 2012-12-31 | $6.30bn | us-gaap:GrossProfit |
| Gross profit | 12 months2012-01-01 to 2012-12-31 | $22.51bn | us-gaap:GrossProfit |
| Operating income | 3 months2012-10-01 to 2012-12-31 | $2.30bn | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2012-01-01 to 2012-12-31 | $7.23bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2012-01-01 to 2012-12-31 | $561.0m | us-gaap:InterestExpense |
| Income tax | 12 months2012-01-01 to 2012-12-31 | $2.44bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2012-10-01 to 2012-12-31 | $1.13bn | us-gaap:ProfitLoss |
| Net income | 12 months2012-01-01 to 2012-12-31 | $3.88bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2012-10-01 to 2012-12-31 | $0.90 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2012-01-01 to 2012-12-31 | $3.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2012-10-01 to 2012-12-31 | $0.91 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2012-01-01 to 2012-12-31 | $3.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2012-01-01 to 2012-12-31 | 1,280,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2012-01-01 to 2012-12-31 | $6.67bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2012-01-01 to 2012-12-31 | $2.03bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2012-01-01 to 2012-12-31 | $829.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 12 months2012-01-01 to 2012-12-31 | $4.33bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2012-12-31 | $1.38bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-12-31 | $19.85bn | us-gaap:AssetsCurrent |
| Total assets | At period end2012-12-31 | $65.91bn | us-gaap:Assets |
| Current liabilities | At period end2012-12-31 | $13.79bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2012-12-31 | $9.13bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2012-12-31 | $5.0m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2012-12-31 | $690.0m | us-gaap:ShortTermBorrowings |
Source: SEC EDGAR, the filing index for accession 0001104659-13-011354. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.